Daily Sepsis Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
The most impactful studies identified a novel DDX3x–histone lactylation–NINJ1 axis driving PANoptosis in sepsis-associated acute kidney injury, demonstrated Cul4B-mediated suppression of NLRP3 inflammasome activation in sepsis-induced lung injury, and externally validated computable pediatric sepsis phenotypes across Argentina and the United States. Together, these papers advance mechanistic understanding, identify therapeutic targets, and support phenotype-guided pediatric sepsis trials.
Research Themes
- Epigenetic and inflammatory mechanisms of sepsis-associated organ injury
- Novel molecular targets for sepsis-induced acute kidney and lung injury
- Computable phenotyping and precision clinical trials in pediatric sepsis
Selected Articles
1. DDX3x Regulates NINJ1 Transcription via Histone Lactylation in Sepsis Associated-Acute Kidney Injury.
This mechanistic study showed that lactate-induced H3K9/18/27 lactylation activates NINJ1 transcription and promotes PANoptosis in sepsis-associated acute kidney injury. DDX3x was identified as a previously unreported delactylase, and its agonist Odetiglucan reduced histone lactylation, NINJ1 transcription, PANoptosis, and kidney injury in cecal ligation and puncture mice and LPS-stimulated HK-2 cells.
Impact: The study identifies a previously unrecognized epigenetic–transcriptional pathway linking lactate accumulation to tubular cell death and provides a pharmacologically addressable target. The results move beyond association toward a multi-level mechanism with in vivo therapeutic proof of concept.
Clinical Implications: DDX3x-enhancing strategies could eventually provide targeted treatment for sepsis-associated acute kidney injury, but clinical application requires confirmation of pharmacokinetics, safety, organ selectivity, and efficacy in larger mammalian models before human trials.
Key Findings
- Lactate promoted H3K9/18/27 lactylation, NINJ1 transcription, and PANoptosis in sepsis-associated acute kidney injury models.
- DDX3x was identified as a delactylase that regulates H3K9/18/27 lactylation and NINJ1 expression.
- The novel DDX3x agonist Odetiglucan alleviated sepsis-associated acute kidney injury in cecal ligation and puncture mice and LPS-induced HK-2 cells.
Methodological Strengths
- The mechanism was examined across cecal ligation and puncture mice, LPS-stimulated renal epithelial cells, and macrophage-related experimental systems.
- The study integrated genetic manipulation, molecular interaction and lactylation assays, cellular death analyses, and pharmacologic intervention.
Limitations
- The evidence is preclinical, and the safety, dosing, tissue distribution, and therapeutic window of Odetiglucan in humans are unknown.
- The reported mechanism was primarily evaluated in experimental acute kidney injury models and may not represent the molecular heterogeneity of human sepsis.
Future Directions: Future studies should validate DDX3x activity and NINJ1-dependent PANoptosis in human sepsis samples, establish pharmacologic exposure–response relationships, and test whether intervention improves renal recovery and survival without impairing host antimicrobial defense.
Sepsis associated-acute kidney injury (SA-AKI), a severe complication of sepsis, is characterized by impaired tubular injury that can ultimately cause renal failure and patient mortality. Both histone and non-histone lactylation and cellular PANoptosis have been implicated in the pathogenesis of SA-AKI. In this study, we investigated how lactylation in histone H3 at lysines 9, 18, and 27 (H3K9/18/27la) modulates PANoptosis in SA-AKI. Our findings revealed that lactate triggers PANoptosis by promoting H3K9/18/27la through the activation of Ninjurin-1 (NINJ1) gene transcription in SA-AKI.
2. Cul4B up-regulation attenuates sepsis-induced acute lung injury by promoting NLRP3 ubiquitination and inhibiting NLRP3 inflammasome activation.
Cul4B was downregulated in sepsis-induced acute lung injury, and lung-specific overexpression reduced pulmonary inflammation, epithelial barrier damage, and histopathologic injury. Myeloid-specific Cul4B deletion worsened disease, while Cul4B interacted with NLRP3 and promoted its ubiquitination to suppress inflammasome activation; the small molecule MN-08 increased Cul4B expression and protected against injury.
Impact: This paper establishes Cul4B-dependent NLRP3 ubiquitination as a mechanistic checkpoint controlling inflammatory lung injury in sepsis. It also connects the pathway to a small molecule, creating a plausible starting point for targeted therapeutic development.
Clinical Implications: Cul4B–NLRP3 signaling may become a therapeutic strategy for sepsis-induced acute lung injury and could inform development of inflammasome-modulating agents, although efficacy and safety in human sepsis remain untested.
Key Findings
- Cul4B expression was reduced in lung tissues from two mouse models of sepsis-induced acute lung injury.
- Lung-specific Cul4B overexpression attenuated lung injury, whereas myeloid-specific deletion exacerbated epithelial barrier damage and inflammation.
- Cul4B interacted with NLRP3 and promoted NLRP3 ubiquitination, while MN-08 increased Cul4B expression and suppressed inflammasome activation.
Methodological Strengths
- The study combines two sepsis-induced lung injury mouse models with lung-specific gain-of-function and myeloid-specific loss-of-function approaches.
- Mechanistic conclusions are supported by histopathology, inflammatory and barrier-function assessments, cell-based assays, protein interaction studies, and ubiquitination analyses.
Limitations
- The findings are derived mainly from mouse and cell models, so their relevance to heterogeneous human sepsis-induced lung injury is uncertain.
- The abstract does not establish whether MN-08 improves survival, respiratory outcomes, or clinically relevant endpoints in vivo.
Future Directions: Further work should test MN-08 in clinically relevant large-animal and humanized sepsis models, define the therapeutic window and effects on host defense, and determine whether Cul4B or NLRP3 ubiquitination biomarkers identify patients most likely to benefit.
BACKGROUND AND PURPOSE: Cullin 4B (Cul4B), a scaffold protein of CUL4B-RING E3 ligase complex, functions primarily as a negative regulator of inflammation. This study aims to investigate its role in acute lung injury (ALI) and NLRP3 ubiquitination. EXPERIMENTAL APPROACH: Cul4B expression and distribution were examined in two sepsis-induced ALI mouse models. Lung-specific overexpression and myeloid-specific Cul4B deletion were applied to evaluate its effects on lung histopathology, pulmonary inflammation, and alveolar capillary barrier dysfunction. The role of Cul4B in NLRP3 inflammasome activation was evaluated in THP-1 cells and Cul4B-deficient BMDMs. Cul4B-NLRP3 interaction and Cul4B-mediated NLRP3 ubiquitination were determined.
3. Comparison of a Computable Pediatric Sepsis Phenotype Tool in Argentinian and U.S. Cohorts.
This retrospective cross-national cohort study evaluated a computable tool using 25 bedside variables to classify pediatric sepsis into four phenotypes. PedSep D consistently had the highest mortality in Argentina and the United States and showed heterogeneous responses to anti-inflammatory therapy, supporting its use for enrichment and stratification in multinational pediatric randomized trials.
Impact: The study provides independent cross-country validation of a computable pediatric sepsis phenotype and links phenotype membership to mortality and treatment-response heterogeneity. This directly supports precision-trial design rather than assuming that all pediatric sepsis is biologically homogeneous.
Clinical Implications: The PedSep tool could help pediatric intensive care teams identify children with particularly high risk and may enable phenotype-enriched enrollment in trials of dexamethasone or methylprednisolone plus immunoglobulin. It is not yet a substitute for clinical judgment or a validated bedside treatment-guidance instrument.
Key Findings
- The Argentine cohort included 99 children from 51 PICUs and the U.S. cohort included 404 children from nine PICUs.
- Mortality was 20.2% in Argentina and 11.14% in the United States, while PedSep D mortality was similar between countries at 32.14% and 33.93%, respectively.
- PedSep D showed heterogeneous responses to anti-inflammatory therapies, and power calculations estimated 55 PedSep D patients per treatment arm for a future trial.
Methodological Strengths
- The tool was evaluated in an independent Argentine cohort and compared with a previously studied U.S. cohort across multiple pediatric intensive care units.
- The analysis examined phenotype prevalence, mortality, treatment-response heterogeneity, and prospective trial sample-size requirements.
Limitations
- Both cohorts were retrospective, and the Argentine sample was substantially smaller than the U.S. cohort.
- The tool requires 25 variables measured at 24 hours, which may limit early applicability and may be affected by differences in care processes, data availability, and case mix between countries.
Future Directions: Prospective international validation should assess real-time implementation, calibration across healthcare settings, and whether phenotype-guided therapy improves outcomes. Future randomized trials should prespecify phenotype-based stratification and evaluate the reproducibility of treatment-response heterogeneity.
OBJECTIVE: Sepsis is a leading cause of mortality in low- and middle-income countries. This study identifies computable pediatric sepsis phenotypes (PedSep A, B, C, and D) previously derived in a U.S. cohort in a new independent Argentine cohort to assess plausibility for its use in personalized clinical trials in Pan-American children. DESIGN: This retrospective cohort study uses data from the Argentinian ESSPED2 (Estudio Sepsis y Shock Séptico Pediátrico 2) Registry and the Phenotyping Pediatric Sepsis-Induced Multiple Organ Failure U.S. study. SETTING: The Argentine cohort was recruited from 51 PICUs between September 15 and December 15, 2021. The U.S. cohort involved nine PICUs between 2015 and 2017.